Showing results (471-480 of 527) with videos related to

Sort By:
Pageof 53
The Annals of Thoracic Surgery|July 24, 2019
High-Risk Factors for Recurrence of Stage I Lung Adenocarcinoma: Follow-up Data From JCOG0201Yasuhiro Tsutani, Kenji Suzuki, Teruaki Koike, et al.
JTO Clinical and Research Reports|August 21, 2023
Prospective, Multi-Institutional Observational Study of Deterioration in Activities of Daily Living in Elderly Patients After Lung Cancer SurgeryHidefumi Takei, Hideo Kunitoh, Masashi Wakabayashi, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|October 5, 2017
Model of lung cancer surgery risk derived from a Japanese nationwide web-based database of 78 594 patients during 2014-2015Shunsuke Endo, Norihiko Ikeda, Takashi Kondo, et al.
Scientific Reports|May 13, 2021
Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patientsKakuhiro Yamaguchi, Satoshi Nakao, Hiroshi Iwamoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2019
Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u>ulticenter, Op<u>e</u>n-label, Single-a<u>r</u>m, Japanese Phase II study in Mal<u>i</u>gnant Pleural Meso<u>t</u>helioma (MERIT)Morihito Okada, Takashi Kijima, Keisuke Aoe, et al.
Cell Communication and Signaling : CCS|October 30, 2019
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinomaMasaoki Ito, Carles Codony-Servat, Jordi Codony-Servat, et al.
Esophagus : Official Journal of the Japan Esophageal Society|November 10, 2020
Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)Masanobu Takahashi, Ken Kato, Morihito Okada, et al.
The Journal of Thoracic and Cardiovascular Surgery|September 13, 2023
Long-term outcome of patients with peripheral ground-glass opacity-dominant lung cancer after sublobar resectionsIchiro Yoshino, Yasumitsu Moriya, Kenji Suzuki, et al.
Cancer Science|December 23, 2025
Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From Checkmate 77TFumihiro Tanaka, Yasutaka Watanabe, Shunichi Sugawara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 11, 2025
Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L)Akira Hamada, Junichi Soh, Akito Hata, et al.
Pageof 53